MedTrace Logo

ctDNA Methylation Sequencing for Myeloma

NCT05578625 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2022-10-13

No results posted yet for this study

Summary

1. To carry out research on minimal residual disease (MRD) monitoring in patients with multiple myeloma (MM) based on plasma circulating tumor DNA (ctDNA) methylation sequencing, which aims to explore new MRD detection methods for MM;
2. Carry out ctDNA-based methylation sequencing in newly diagnosed, remission, and, relapsed MM patients, to track the clonal evolution patterns; and explore the in the initial diagnosis-remission-relapse stage of MM, track the clonal evolution characteristics of methylation profiles in MM patients during the disease progression.

Conditions

Interventions

OTHER

plasma circulation DNA methylation sequencing

10 mL of peripheral blood will be drawn from 60 multiple myeloma patients at diagnosis, 4 months post-induction, and at relapse, and cell-free DNA is then extracted and undergo bisulfite methylation sequencing.

Sponsors & Collaborators

  • MethylGene Tech Co., Ltd. China

    collaborator UNKNOWN

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Principal Investigators

  • InsituteHBDH · Institute of Hematology and Blood Diseases Hospital,Tianjin, China, 300020

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-31
Primary Completion
2023-08-31
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05578625 on ClinicalTrials.gov